Division Of Antiviral Products Advisory Committee Meeting

2

NDA 22-145: Isentress™ (raltegravir potassium)

Applicant: Merck & Co., Inc.

Formulation: 400 mg tablets

Indication: HIV-1 treatment-experienced adult patients